Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies

Leukemia. 2019 Oct;33(10):2527-2530. doi: 10.1038/s41375-019-0481-1. Epub 2019 May 13.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenine / analogs & derivatives
  • Adult
  • Aged
  • Aged, 80 and over
  • B-Lymphocytes / drug effects*
  • Female
  • Humans
  • Incidence
  • Male
  • Middle Aged
  • Neoplasms / drug therapy*
  • Opportunistic Infections / chemically induced*
  • Opportunistic Infections / epidemiology*
  • Piperidines
  • Pyrazoles / adverse effects*
  • Pyrazoles / therapeutic use*
  • Pyrimidines / adverse effects*
  • Pyrimidines / therapeutic use*
  • Young Adult

Substances

  • Piperidines
  • Pyrazoles
  • Pyrimidines
  • ibrutinib
  • Adenine